Formulation for menopausal women

Abstract

The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and / or relief from systems associated with menopause, as well as prophylactic effects, and methods for using same.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation application of co-pending U.S. patent application Ser. No. 11 / 023,871 filed Dec. 22, 2004, said application being a continuation of U.S. patent application Ser. No. 10 / 131,236, filed Apr. 25, 2002; said application being a continuation of U.S. patent application Ser. No. 09 / 409,059, filed Sep. 30, 1999 now issued as U.S. Pat. No. 6,479,545, the entire contents of which are hereby incorporated by reference in their entirety.BACKGROUND OF THE INVENTION[0002]The present invention is directed to novel compositions for use by premenopausal women and menopausal women for the purpose of providing improved nutritional support and / or relief from the symptoms of menopause, as well as to methods for using same.[0003]Menopause, the transition from the reproductive stage to the non-reproductive stage of a woman's life, is characterized primarily by the cessation of menstruation. However, menopause has come to signify...

AI Technical Summary

Benefits of technology

[0097]Another embodiment is a method for reducing the possibility of premature menopause, which comprises: administering an essential fatty acid to a woman prior to menopause, said fatty acid being selected from the group consisting of a linoleic acid compound, a linolenic acid compound, a docosahexaenoic acid compound, an omega-3 fatty acid compound, an omega-2 fatty acid compound, a derivative thereof and a combination thereof; wherein said essential fatty acid is administered in an amount sufficient to reduce the risk of premature menopause.

Problems solved by technology

Lack of sleep due to disturbance by recurring hot flashes contributes to fatigue and irritability.

Menopause is also characterized by osteoporosis, or loss of bone density, resulting in increased bone fractures and vertebral column collapse.

However, estrogen therapy is not without its limitations.

In some instances the side effects of estrogen therapy can be quite severe.

These side effects include increased risk of certain cancers, such as breast cancer.

Although treatments with progestin have been shown to counter these adverse side effects, postmenopausal women treated with such an estrogen-progestin regimen frequently experience undesirable uterine bleeding.

Further, hormone therapy alone is insufficient to meet the varied and heightened nutritional requirements of a woman during this phase in her life.

However, while vitamin and mineral supplements providing calcium for women is known in the art, conventional supplements fail to meet other nutritional requirements of menopausal women.

Specifically, conventional supplements lack certain fatty acids which are especially useful to treat symptoms of fatigue or tiredness commonly experienced by a woman undergoing menopause.

However, conventional nutritional supplements fail to include these two fatty acids.

Further, the oil vehicle is high in glycerides of polyunsaturated fatty acids.

However, the previously disclosed formulations are deficient for various reasons.

In particular, none of the previously disclosed formulations contain critical components, such as essential fatty acids or calcium, in amounts specifically tailored to meet the needs of premenopausal and menopausal women.

Moreover, the previously disclosed formulations fail to disclose the significance of the proportion of the various components to one another.

Images